Home » Topics » BioWorld Science

BioWorld Science
RSS

First patient dosed in a phase I study of ARX-517

Aug. 4, 2021

Antibe places its AME study of otenaproxesul on required pause

Aug. 4, 2021

LSD1 as potential therapeutic target in heart failure

Aug. 4, 2021

Cyclin C controls responses to PARP inhibitor treatment in BRCA2-deficient cells

Aug. 4, 2021

Luye Pharma files IND in U.S. to study next-generation VMAT2 inhibitor LY-03015

Aug. 3, 2021

FDA authorizes IND for phase I testing of Sorrento's CD38 DAR-T cell therapy candidate

Aug. 3, 2021

ACD-856 shows preclinical effects on cognition, enters phase I study

Aug. 3, 2021

Annovis reports interim phase II data on Posiphen in Alzheimer's and Parkinson's disease

Aug. 3, 2021

Dosing underway in phase I/II study of KRAS G12C inhibitor JAB-21822

Aug. 3, 2021

CTA approved in Vietnam for phase I/II/III study of SARS-CoV-2 vaccine ARCT-154

Aug. 3, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 12, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
LINC01116 has prognostic value in lung cancer, study shows
BioWorld MedTech
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...